CADTH is inviting stakeholders to attend an information and feedback session on 5 February 2015 regarding phase II of the transition of pCODR to CADTH, including the work to better align the pCODR and CADTH Common Drug Review (CDR) processes.

CADTH is hosting two separate sessions — one for patient advocacy groups and clinicians, and another for pharmaceutical manufacturers, associations, and consultants.

For more details, go to: http://cadth.ca/en/events/2015/stakeholder-engagement-sessions-transfer-of-pcodr